Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB

Ratings ESG MSCI

Ratings Bio-Rad Laboratories, Inc.: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
Highlights: Bio-Rad Laboratories, Inc.
  • The company is in a robust financial situation considering its net cash and margin position.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Weaknesses: Bio-Rad Laboratories, Inc.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • The firm trades with high earnings multiples: 41.11 times its 2026 earnings per share.
  • The company's enterprise value to sales, at 3.27 times its current sales, is high.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • Most analysts recommend that the stock should be sold or reduced.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The group usually releases earnings worse than estimated.

Rating Financials

Bio-Rad Laboratories, Inc. SectorGermany

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

-

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

-
More ratings

Rating Valuation

Bio-Rad Laboratories, Inc. SectorGermany

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

-

Equity Valuation

P/E

PBR

Dividend Yield

-

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Bio-Rad Laboratories, Inc. SectorGermany

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

-

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Bio-Rad Laboratories, Inc. SectorGermany

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Bio-Rad Laboratories, Inc. SectorGermany

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
9.13B
BBB
187B
BBB
110B
BBB
62.02B
AA
53.79B
AAA
48.79B
A
31.33B
BBB
30.27B
A
24.53B
AA
22.59B
AAA
-
Average 57.92B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. BIO Stock
  4. BUWA Stock
  5. Ratings Bio-Rad Laboratories, Inc.